Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study-Reference-Cited by-同舟云学术

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study

Published:2011-01 Issue:1 Volume:6 Page:161-168
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Vergnenegre Alain,Corre Romain,Berard Henri,Paillotin Dominique,Dujon Cecile,Robinet Gilles,Crequit Jacky,Bota Suzanna,Thomas Pascal,Chouaid Christos

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Economics of treatments for non-small cell lung cancer;Chouaid;Pharmacoeconomics,2009

2. Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2009

3. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials;Tassinari;Chest,2009

4. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer;Hensing;Lung Cancer,2005

5. Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice;Tassinari;Ann Oncol,2010

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models;PharmacoEconomics - Open;2024-02-10

2. Clinical Pharmacology in Oncology;Tata Memorial Centre Textbook of Oncology;2024

3. The cost of chemotherapy administration: a systematic review and meta-analysis;The European Journal of Health Economics;2021-03-09

4. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies;Current Medical Research and Opinion;2020-11-28

5. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer;Clinical Drug Investigation;2019-10-03